Methionine aminopeptidase-2 (METAP2) inhibitors have demonstrated potent antiangiogenic and antitumor effects in patients with late-stage cancer (1–3) as well as highly favorable metabolic effects, including significant weight loss and improvements in insulin sensitivity and blood lipid levels in obese patients (4, 5). Here, METAP2 is linked to cancer.